| 000 | 05872cam a2200421Mi 4500 | ||
|---|---|---|---|
| 001 | 95251 | ||
| 003 | ES-MaUEC | ||
| 005 | 20230102112654.0 | ||
| 006 | m o d | ||
| 007 | cr cnu---unuuu | ||
| 008 | 170121s2017 sz o 001 0 eng d | ||
| 020 |
_a3319329731 _q(electronic bk.) |
||
| 020 |
_a9783319329734 _q(electronic bk.) |
||
| 020 | _z3319329715 | ||
| 020 |
_z9783319329710 _q(print) |
||
| 035 |
_a(OCoLC)969646235 _z(OCoLC)969853599 _z(OCoLC)974650807 _z(OCoLC)981819146 _z(OCoLC)1005822822 _z(OCoLC)1011954005 |
||
| 040 |
_aEBLCP _cEBLCP _dN$T _dGW5XE _dOCLCF _dUAB _dOCLCQ _dNJR _dYDX _dOCLCO _dIDEBK _dUPM _dIOG _dOCLCO _dMERER _dESU _dZ5A _dOCLCO _dOCLCQ _dOHS _dOCLCO _dJBG _dIAD _dOCLCO _dICW _dOCLCO _dICN _dOCLCQ _dOCLCO _dOTZ _dOCLCQ _dVT2 _dOCLCO _dOCLCQ _dU3W _dES-MaUEC _bspa |
||
| 050 | 4 |
_aR1 _b2017 EB |
|
| 245 | 0 | 0 |
_aPediatric and adolescent oncofertility : _bbest practices and emerging technologies _cTeresa K. Woodruff, Yasmin C. Gosiengfiao, editors. |
| 264 | 1 |
_aCham _bSpringer International Publishing _c2017 |
|
| 300 | _a1 recurso en línea (304 páginas) | ||
| 336 |
_aTexto _btxt _2rdacontent |
||
| 337 |
_aelectrónico _bc _2rdamedia |
||
| 338 |
_arecurso electrónico _bcr _2rdacarrier |
||
| 347 |
_atext file _bPDF _2rda |
||
| 505 | 0 | _aPreface; Contents; Contributors; Chapter 1: Fertility Risk with Cancer Therapy; Introduction; Estimating Risk; Males; Females; Minimizing Risk; Gonadotropin-Releasing Hormone Agonist; Imatinib; Bone Marrow-Derived Mesenchymal Stem Cells; Sphingosine-1-phosphate (S1P); Tamoxifen; AS101; Granulocyte Colony-Stimulating Factor (G-CSF); Conclusion; References; Chapter 2: Fertility Preservation Options for Female Pediatric and Adolescent Oncology Patients; Introduction; Protection of Ovarian Function; Ovarian Transposition; Ovarian Suppression; Assisted Reproductive Endocrinology. | |
| 505 | 8 | _aCombined Hormonal Contraception (Pill, Patch, Ring) Levonorgestrel IUD for Menstrual Suppression; Appendix: Medical Eligibility Criteria for Contraceptive Use; References; Chapter 5: Female Sexual Function in Childhood, Adolescent, and Young Adult Cancer Survivors; Scope of the Problem; Barriers to Care; Sexual Development; Infancy and Childhood; Preadolescence; Adolescence; Sexual Development in Survivors of Childhood Cancer; Risk Factors for Sexual Dysfunction; Long-Term and Late Effects of Cancer Treatment on Sexual Functioning; Physiologic Effects; Psychosocial Effects. | |
| 505 | 8 | _aEmbryo and Oocyte Cryopreservation Ovarian Tissue Cryopreservation and Transplantation; Assessment of Ovarian Reserve; Reproductive Options Post Therapy; Donor Oocytes and Embryos; Fertility Preservation Post Therapy; Gestational Carrier; Adoption; Access to Fertility Preservation; Ethical Considerations; Future Directions; Generation of Gametes from Somatic Cells; Coverage of Fertility Preservation by Insurance; Conclusion; References; Chapter 3: Assessing Ovarian Reserve; Background; Assessing Ovarian Reserve; Menstrual Cycles; Antral Follicle Counts and Ovarian Volume. | |
| 505 | 8 | _aEndocrine Hormones Follicle-Stimulating Hormone (FSH), Inhibin B, and Estradiol; Anti-Mullerian Hormone (AMH); Current Data on AMH in Children Receiving Cancer Therapy; Ovarian Reserve Testing as a Predictor of Menstrual Pattern and Fertility; Effect of Female Hormones on Ovarian Reserve Testing; References; Chapter 4: Contraception and Menstrual Suppression for Adolescent and Young Adult Oncology Patients; Contraception; Survivors; Menstrual Regulation and Suppression; GnRH Agonist; Progestin-Only Pills; Depot Medroxyprogesterone Acetate. | |
| 505 | 8 | _aSocial Effects Female Sexual Dysfunction; Female Sexual Interest/Arousal Disorder (FSIAD); Female Orgasmic Disorder; Genito-pelvic Pain/Penetration Disorder (GPPPD); Screening and Assessment; Treatment; Education and Setting of Expectations; Non-pharmacologic Therapies; Pharmacologic Therapies; When to Refer; Conclusion; References; Chapter 6: Vitrification of Ovarian Tissue for Fertility Preservation; Introduction; Vitrification: Facts and Fallacies; Development of Ovarian Tissue Vitrification Based on Cryobiological Principles; Endpoints of Vitrification Success. | |
| 520 | 3 | _aReflecting the increasing interest in fertility management for pediatric and adolescent patients and fulfilling an urgent need to have a comprehensive guide to the management of these individuals, this is the first book of its kind to present a comprehensive discussion of pediatric and adolescent oncofertility. It carefully examines the impact of pediatric cancer and cancer therapy on fertility and presents both current and emerging fertility preservation techniques for both males and females, such as cryopreservation. Fertility concerns beyond cancer are also discussed, including disorders of sexual differentiation, gender dysphoria and thalassemia. Practical chapters on pediatric oncofertility in the clinic round out the book, covering setting up a practice, counseling and consent, disclosure and insurance considerations. Concluding chapters document fertility preservation techniques and outcomes internationally, with contributions from Portuguese, Brazilian and Japanese authors. Timely and wide-ranging, Pediatric and Adolescent Oncofertility is an ideal resource for reproductive medicine specialists, pediatric oncologists, and primary care physicians treating pediatric and adolescent cancer patients looking to protect fertility options. | |
| 650 | 7 |
_aCáncer en niños _2embne _0(OCoLC)fst00845581 _0 _9157453 |
|
| 700 | 1 | _aGosiengfiao, Yasmin C. | |
| 700 | 1 |
_aWoodruff, Teresa K. _988137 |
|
| 856 | 4 | 0 |
_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=http://link.springer.com/10.1007/978-3-319-32973-4 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid) |
| 988 | _aSpringer_Medicine_2017 | ||
| 998 |
_b02/2018 _dz _e- _zSI |
||
| 999 |
_c95251 _d95251 _x1 |
||